Celon Pharma S.A.

Climate Impact & Sustainability Data (2021, 2021-01 to 2021-06)

Various educational and information campaigns targeted at employees, aimed at promoting SARS-COV2 vaccinations. Ensured access to diagnostic tests for its employees.

Covid-19 pandemic and the Russia and Ukraine conflict.
High uncertainty and volatility of events in the current economic situation.
Increase in operating costs driven by intensification of R&D projects, inflation, market wage pressure, and market energy costs increase.
Concentration risk in sales and trade receivables with a few key clients.
Tax risk in Poland due to ambiguities and inconsistencies in regulations.

Ongoing analysis of financial and operational risks.
Implemented preventive measures to ensure continuity of operations and employee safety during the pandemic.
Sales expansion in the generic drug segment to maintain EBITDA.
Active policy of collecting receivables from customers with overdue payments.
Minimising supply risk through authorising at least two independent alternative suppliers for key components.

Frameworks Used: IFRS

Medium-term Goals:

Introduction of at least two drug candidates into clinical development per year
Completion of phase II drug trials in at least 6 therapeutic indications
Initiation of phase III programs (independently or in collaboration with other partners) for at least three therapeutic indications
Completion of phase III trials of Falkieri (esketamine DPI) and submission of applications to the FDA and EMA
Signing of significant partnership agreements.
Continued geographical expansion of Salmex
Strengthening the market position in the main EU markets
Achieving a double-digit CAGR growth rate in export sales between 2021 and 2025
Completing clinical development and obtaining marketing authorization for Salmex in China and the US
Expansion of the portfolio of generic medicines in key therapeutic areas (respiratory diseases and central nervous system diseases).

Short-term Goals:

Identify the best commercial solutions, including acquiring commercial partners to pursue phase III clinical development and commercialization of its projects.

Reduced growth dynamics observed for the overall domestic drug market and one-off impact on sales growth in 1H20 caused by various sales channels stocking up in fear of the pandemic.
Weakening of the Polish currency and the significant energy cost rise.
Delays in the clinical trial monitoring processes were caused by difficulties in access to source data in study sites resulting from the COVID-19 pandemic in 1Q2021 and 2Q2021.

Swift withdrawal of Valzek from the market and simultaneous launching of the manufacturing process for new batches which meet current qualitative requirements.
Diversification of suppliers of raw materials required to manufacture the Company's products.
Long-standing policy of addressing supply risks by authorizing at least two independent alternative suppliers for key components.